Merck Serono big pharma deals with Quintiles in a new, five-year clinical co-development agreement.
This strategic pharma deals partnership is the first-of-its-kind between a biopharmaceutical company and a biopharmaceutical services provider, creating a comprehensive process that integrates the expertise and experience from both organizations into a single, well-aligned clinical development engine.
In a novel approach to clinical development that is founded on a shared commitment to cost-disciplined science, the collaboration is intended to optimize productivity in the design and execution of studies with a focus on quality, speed and efficiency.
Under this pharma deals agreement, Merck Serono (a big pharma company) will shape and lead the strategy of its clinical development programs, with Quintiles directing clinical trial planning and execution. Quintiles also will be a key contributor to the big pharma company's future clinical trial design activities.
In this capacity, Quintiles will focus on delivering superior performance based on optimized clinical trial design and execution strategies, using highly efficient processes and proven technologies.
To fully leverage the expertise of both organizations in the pharma deals, leaders from Quintiles will collaborate in strategic decision-making processes affecting the development of the Merck Serono portfolio.
Quintiles will be the sole primary provider of Merck Serono’s outsourced clinical development services for its global clinical programs within the terms of the pharma deals.
Daily news stories
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Merck KgaA / Merck Serono
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity